Obicetrapib’s Lipid-Lowering Effect Improves Cardiovascular Event Risk

Obicetrapib, a highly selective and potent cholesteryl ester transfer protein (CETP), is associated with a greater reduction in cardiovascular event rates compared to placebo, according to a pooled analysis of the BROOKLYN and BROADWAY phase 3…